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Transforming growth factor-β enhances Rho-kinase
activity and contraction in airway smooth muscle
via the nucleotide exchange factor ARHGEF1
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Jeremy P. T. Ward and Greg A. Knock
Division of Asthma, Allergy and Lung Biology, Faculty of Life Sciences and Medicine, King’s College London, London, SE1 1UL, UK
Edited by: Harold Schultz & Troy Hornberger
Key points
 Transforming growth-factor-β (TGF-β) and RhoA/Rho-kinase are independently implicated
in the airway hyper-responsiveness associated with asthma, but how these proteins interact is
not fully understood.
 We examined the effects of pre-treatment with TGF-β on expression and activity of RhoA,
Rho-kinase andARHGEF1, an activator ofRhoA, aswell as onbradykinin-induced contraction,
in airway smooth muscle.
 TGF-β enhanced bradykinin-induced RhoA translocation, Rho-kinase-dependent
phosphorylation and contraction, but partially suppressed bradykinin-induced RhoA
activity (RhoA-GTP content).
 TGF-β enhanced the expression ofARHGEF1,while a small interferingRNAagainst ARHGEF1
and a RhoGEF inhibitor prevented the effects of TGF-β on RhoA and Rho-kinase activity and
contraction, respectively.
 ARHGEF1 expression was also enhanced in airway smooth muscle from asthmatic patients
and ovalbumin-sensitized mice.
 ARHGEF1 is a key TGF-β target gene, an important regulator of Rho-kinase activity
and therefore a potential therapeutic target for the treatment of asthmatic airway hyper-
responsiveness.
Abstract Transforming growth factor-β (TGF-β), RhoA/Rho-kinase and Src-family kinases
(SrcFK) have independently been implicated in airway hyper-responsiveness, but how they inter-
act to regulate airway smooth muscle contractility is not fully understood. We found that TGF-β
pre-treatment enhancedacute contractile responses tobradykinin (BK) in isolated rat bronchioles,
and inhibitors of RhoGEFs (Y16) and Rho-kinase (Y27632), but not the SrcFK inhibitor PP2,
prevented this enhancement. In cultured human airway smooth muscle cells (hASMCs), TGF-β
pre-treatment enhanced the protein expression of the Rho guanine nucleotide exchange factor
ARHGEF1, MLC20, MYPT-1 and the actin-severing protein cofilin, but not of RhoA, ROCK2
or c-Src. In hASMCs, acute treatment with BK triggered subcellular translocation of ARHGEF1
and RhoA and enhanced auto-phosphorylation of SrcFK and phosphorylation of MYPT1 and
MLC20, but induced de-phosphorylation of cofilin. TGF-β pre-treatment amplified the effects
of BK on RhoA translocation and MYPT1/MLC20 phosphorylation, but suppressed the effects
of BK on RhoA-GTP content, SrcFK auto-phosphorylation and cofilin de-phosphorylation.
In hASMCs, an ARHGEF1 small interfering RNA suppressed the effects of BK and TGF-β on
RhoA-GTP content, RhoA translocation andMYPT1 andMLC20 phosphorylation, butminimally
influenced the effects of TGF-β on cofilin expression and phosphorylation. ARHGEF1 expression
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was also enhanced in ASMCs of asthmatic patients and in lungs of ovalbumin-sensitized
mice. Our data indicate that TGF-β enhances BK-induced contraction, RhoA translocation
and Rho-kinase activity in airway smooth muscle largely via ARHGEF1, but independently of
SrcFK and total RhoA-GTP content. A role for smooth muscle ARHGEF1 in asthmatic airway
hyper-responsiveness is worthy of further investigation.
(Received 29 July 2017; accepted after revision 19 October 2017; first published online 25 October 2017)
Corresponding author G. Knock: Division of Asthma, Allergy and Lung Biology, Faculty of Life Sciences
and Medicine, 1.20 Henriette Raphael House, Guy’s Campus, King’s College London, London SE1 1UL, UK.
Email: greg.knock@kcl.ac.uk
Introduction
In healthy subjects, airway smooth muscle (ASM) tone
and airflow resistance are low, while in subjects with
allergic asthma, exposure to allergens sensitizes airways
to constrictor stimuli, resulting in inappropriate episodic
ASM constriction (airway hyper-responsiveness, AHR)
and long-term remodelling (Doeing & Solway, 2013).
These smooth muscle phenotypic changes are triggered
by inflammatory mediators, produced in the airways in
response to allergen sensitization. One of these mediators,
transforming growth factor-beta (TGF-β), is produced at
higher basal levels in asthmatic airways and is increased
several-fold after allergen challenge (Redington et al. 1997;
Torrego et al. 2007) up to levels that correlate with
the severity of AHR and remodelling (Matsunaga et al.
2006). In connective tissue, TGF-β induces contractile
protein expression and stress fibre assembly (Vardouli
et al. 2005; Sandbo et al. 2011; Ji et al. 2014), while in
ASM, it can influence both proliferation and hypertrophy
(Halwani et al. 2011) and induce hyper-responsiveness
to bronchoconstrictors (Goldsmith et al. 2006; Oenema
et al. 2012).
Smooth muscle cross-bridge cycling requires MLC20
(myosin light-chain 20-kDa subunit) phosphorylation,
which is in turn dependent on the balance between
activity of Ca2+-induced myosin light-chain kinase and
myosin light-chain phosphatase (MLCP). The latter is
inhibited by phosphorylation of myosin phosphatase
targeting subunit-1 (MYPT1) by Rho-kinase, an effector
of the monomeric G-protein RhoA (Somlyo & Somlyo,
2003). Thus, TGF-β could mediate enhanced ASM
responsiveness to bronchoconstrictors by enhancing
expression or activity of RhoA/Rho-kinase, their down-
stream targets or their upstream regulators. Among
the upstream regulators are the Rho-specific guanine
nucleotide exchange factors (RhoGEFs), a large family
of regulatory proteins that activate members of the Rho
family of small G-proteins by catalysing the exchange of
boundGDP for boundGTP (Bos et al. 2007). Twoof these,
GEF-H1 andNet1, are up-regulated byTGF-β in epithelia,
thus enhancing RhoA-dependent F-actin expression/cell
migration and epithelial-to-mesenchymal transition,
respectively (Tsapara et al. 2010; Papadimitriou et al.
2012). Another RhoGEF, ARHGEF1 (p115-RhoGEF, Lsc),
not previously linked with TGF-β, has been implicated in
the T-cell dysfunction associatedwith allergic asthma, and
in the contractile effects of angiotensin II on hypertensive
vascular smooth muscle (Brown et al. 2007; Guilluy et al.
2010). The role of ARHGEF1 in ASM contraction remains
to be determined.
We have recently confirmed that bradykinin (BK)-
induced MLC20 phosphorylation and contraction in
healthy rat airways and cultured human ASM was
dependent on Rho-kinase activity, which was also partly
mediated via activation of Src-family kinases (SrcFK)
(Shaifta et al. 2015). Both Rho-kinase and SrcFK have
been suggested as potential therapeutic targets in asthma,
bothhavingbeing implicated in experimentalAHR(Chiba
et al. 2005; Schaafsma et al. 2006; Katsumoto et al.
2013). Smooth muscle contraction is also influenced by
factors that regulate actin cytoskeleton re-organization
and contractile apparatus assembly; in several cell types
this is also reportedly mediated by RhoA/Rho-kinase, in
part via inhibitory phosphorylation of cofilin (Arber et al.
1998; Vardouli et al. 2005; Leduc et al. 2016). Conversely,
it has been suggested that, particularly in ASM, cofilin
has an alternative role in promoting actin polymerization,
perhaps independently of Rho-kinase (Zhao et al. 2008;
Zhang et al. 2010). In this study we therefore examined
the long-term effects of TGF-β on BK-induced ASM
contraction, as well as on protein expression and activity
of ARHGEF1, SrcFK, RhoA/Rho-kinase MYPT1/MLC20
and cofilin.
Methods
Ethical approval
All studies with rat tissues were performed in vitro
after animals were killed by an intra-peritoneal sodium
pentobarbital injection. Ovalbumin (OVA) sensitization
and lung function measurement in mice was performed
in accordance with The Animals (Scientific procedures)
Act (1986) and local ethical approval from King’s
College London. Donation of human tissue was obtained
following written informed consent and with the
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approval of the South East London Research Ethics
Committee, REC reference number: 10/H0804/66. All
clinical procedures conformed to the standards set by the
latest Declaration of Helsinki.
Animal tissue
Investigations of airway reactivity in healthy animals
were conducted in isolated small intralobar bronchioles
obtained from male Wistar rats (250 g). Lungs were
removed immediately after killing by lethal injection
(pentobarbital, I.P.). Bronchioles (1 mm in diameter,
2 mm in length) were dissected free of surrounding
parenchyma and placed in cold physiological saline
solution (PSS, composition inmM: 118NaCl; 24NaHCO3;
1 MgSO4; 4 KCl; 5.56 glucose; 0.435 NaH2PO4; 1.8 CaCl2,
pH 7.4). Lung tissue was also obtained from a mouse
model of airway hyper-responsiveness. 129SVJ/Black
Swiss mice were immunized four times at 7 day inter-
vals, with OVA (30 μg ml−1 I.P., OVA-treated), or vehicle
[Al2(OH)3, sham-treated]. They were then challenged
with aerosolized OVA (30 μg ml−1, 2 × 25 min per day
for 4 days). Airway hyper-responsiveness in OVA-treated
mice was confirmed by greater methacholine-induced
reduction in airway dynamic compliance (Cdyn)
compared to sham-treated (P < 0.01) and greater
sensitivity to methacholine compared to sham-treated
(Cdyn half-maximal provocation concentration (PC50)
reduced by 50%, P < 0.001).
Human tissue and cell culture
Human airway smooth muscle cells (hASMCs) were
obtained from healthy volunteers (n = 11; 7 female, 4
male; age range 22–53 years) or volunteers with moderate
asthma (n= 3; allmale; age range 44–53 years), using deep
endobronchial biopsy. Healthy volunteers were selected
based on a life-long absence of respiratory symptoms, and
lung functions within normal limits. Moderate asthmatics
were selected based on the presence of typical symptoms
over at least 2 years, a minimum of 12% reversibility,
forced expiratory volume in 1 sec (FEV1) <80% of pre-
dicted for age, and/or a bronchoconstrictor response to
a methacholine challenge of <8 mg ml−1. All asthmatic
subjects were on a combined therapy of short acting
beta-agonist and inhaled corticosteroids (fluticasone
propionate <500 μg daily or equivalent). Patients
currently receiving leukotriene receptor antagonists,
smokers and pregnant/lactating females were excluded.
ASMbundles were bathed inDulbecco’smodified Eagle
medium (DMEM) containing the following supplements:
10% fetal bovine serum, L-glutamine (2 mM), sodium
pyruvate (1 mM), non-essential amino acids and
amphotericin B (2μg ml−1) and dissected free of adjacent
connective tissue and epithelia. They were then sub-
jected to enzymatic digestion in nominally Ca2+-free
Hepes buffer containing: 5.56 mM glucose, 2 mg ml−1
collagenase Type XI, 1 mg ml−1 papaine, 1 mg ml−1
trypsin inhibitor and 1 mM DTT. Cells were then
dispersed, incubated in DMEM (plus supplements) at
37°C,pH7.4, and typically used for experiments at passage
4–9. hASMCs were seeded onto 60 mm dishes, grown to
confluenceand serumstarved for7days inDMEMwithout
FBS, supplemented with L-glutamine (2 mM), sodium
pyruvate (1 mM), non-essential amino acids (1:100),
amphotericin B (1.5 μg ml−1), gentamicin (50 μg ml−1),
insulin-transferrin-selenium (1:100), 100 μM ascorbate
and bovine serum albumin (BSA) (1%). This prolonged
serum starvation andmedia/supplement combination has
previously been shown to restore andpreserve a contractile
phenotype in ASM (Halayko et al. 1999; Kim et al. 2005).
hASMCs were confirmed as smooth muscle by positive
staining for smooth muscle-specific protein markers, as
described previously (Shaifta et al. 2015).
TGF-β treatments
The long-term effects of TGF-β on tissue and cellular
function and protein expression were examined by
pre-incubation of rat bronchioles or hASMCs for 18–24 h
at concentrations similar to those previously found to
exist in the airways of asthmatic patients (Redington et al.
1997; Torrego et al. 2007). Bronchioles were incubated
for 18 h at 37°C with 30 ng ml−1 TGF-β serum-free
Ham’s F12mediumwith supplements and 0.1%BSA, or in
Ham’s F12medium and supplements/BSA alone (Halayko
et al. 1999; Kim et al. 2005). Following this incubation,
bronchioleswere transferred toPSS for subsequent tension
measurementbywiremyography, in the absenceofTGF-β.
Treatment of hASMCswith 10 ngml−1 TGF-β for 24 hwas
initiated at day 6 of serum starvation, followed bywashout
with serum-freemedia (without TGF-β) for a further 24 h,
prior to acute treatmentswith pharmacological agents and
harvesting.
Tension measurement by wire myography
Bronchioles were mounted on a Mulvany–Halpern small
vessel wire myograph (www.DMT.dk), and bathed in PSS
gassedwith 95%air/5%CO2 at 37°C, for themeasurement
of isometric tension. Bronchioles were stretched
incrementally, and alternately exposed to PSS containing
80 mM [K+] (equimolar substitution for Na+, KPSS)
to determine the point on the length–tension curve at
which optimum active tension development was achieved,
as described previously (Moir et al. 2003). Viability of
bronchioles for tension experiments was confirmed by
active tension generation of at least 2 mN in response to
the last exposure to KPSS. Mean internal diameter after
stretching was typically in the range 300–800 μm.
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RhoA-EmGFP/ARHGEF1-EmGFP cloning
RhoA and ARHGEF1 cDNAs were separately cloned
into pcDNA6.2/C-EmGFP/TOPO to produce C-terminal
Emerald green fluorescent protein (EmGFP) fusion
vectors (Invitrogen Life Technologies, UK). Oligon-
ucleotide primers were designed in accordance with the
manual and using sequences from the GenBank database
(RhoA accession no. BC061732; ARHGEF1 accession
no. BC091218) as follows: RhoA (forward): GTTATGGC
TGCCATCAGGAAGAAACTGG-3′, RhoA (reverse): 5′-
CAAGATGAGGCACCCCGACT-3′, ARHGEF1
(forward): 5′-GAGATGGGAGAAGTCGCCGGAGGGG
C-3′, ARHGEF1 (reverse): 5′-TGAAAGGCCTGTCTG
AGCAGAGCGC-3′. Clones were checked for the correct
orientation using restriction endonuclease digestion and
gel electrophoresis. These were then sent for sequencing
(Source BioScience, Nottingham, UK) and selection.
siRNA design and transfection
The human ARHGEF1 small interfering RNA (siRNA)
was designed as described previously (Knock et al.
2008; Shaifta et al. 2015). The 19 nucleotide target
sequence (position 2057–2075, GenBank accession
no. NM 199002) was synthesized into 64–65 mer
oligonucleotides with BamHI/HindIII overhangs (Sigma,
Poole, UK) and cloned into the expression vector
pSilencer 3.0-H1 (Ambion Inc., Austin, TX, USA). All
clones were purified (EndoFree PlasmidMaxi Kit, Qiagen,
Valencia, CA, USA) and sequenced (Source BioScience).
As a negative control, another siRNA was prepared
using a scrambled mRNA sequence. Transfection was
carried out in detached confluent hASMCs using the
Basic Nucleofector Kit for Primary Mammalian Smooth
Muscle Cells and a nucleofector device (Nucleofector
Technology - Lonza AG, Basel, Switzerland). The medium
was changed the next day and cells were grown for a
further 48 h in DMEM plus supplements, prior to serum
starvation and TGF-β treatment, as described above.
Transfection efficiency was >90%, determined separately
using pmaxGFP (green fluorescent protein expressing
vector) provided in the kit and confirmed by fluorescence
microscopy. The efficiency of ARHGEF1 knockdown
was confirmed by western blot (see Fig. 3). If designed
correctly, siRNA can be a highly specific tool for targeted
gene knockdown (Semizarov et al. 2003). To minimize
any non-specific targeting, candidate siRNAs presenting
more than 16 contiguous nucleotides of sequence identity
with another mRNA were discarded (Birmingham et al.
2007). A BLAST alignment (NCBI, Bethesda, MD,
USA) of the 19 nucleotide ARHGEF1 siRNA sequence
showed only 5 contiguous nucleotide homology to
MLC20 (GenBank accession no. S69022), RhoA (GenBank
accession no. BC061732) and cofilin (GenBank accession
no. D00682), only 6 contiguous nucleotide homology
to PDZ-RhoGEF (ARHGEF11, GenBank accession no.
BC057394), only 7 contiguous nucleotide homology to
LARG (ARHGEF12, GenBank accession no. NM01513)
and ROCK2 (GenBank accession no. NM004850), and
only 9 contiguous nucleotide homology to MYPT1
(GenBank accession no. D87930).
Rho-GTP content measurement by Rhotekin asssay
After treatment, cells were harvested as described above
using MLB lysis buffer made up according to The Rho
Assay Reagent protocol (Millipore-Merck, Billerica, MA,
USA). The lysates were then cleared of insoluble cell debris
by centrifugation, a small amount taken to determine
protein concentration and the remainder immediately
snap frozen and stored at –80°C. In the pull-down assay
the collected samples were quick-thawed and 250–500 μg
of proteinwasmixedwith 20μg of The RhoAssay Reagent
slurry (A GST-tagged fusion protein, corresponding to
residues 7–89 of mouse rhotekin Rho-binding domain
bound to glutathione-agarose) and incubated for 45 min
at 4°C with gentle agitation using a roller mixer. As
a positive control, an extra untreated sample was
pre-incubated with GTPγS for 30 min at 30°C prior to
mixing with The Rho Assay Reagent slurry. After 45 min,
the mixture was centrifuged at 4°C and the supernatant
discarded followed by three washes with ice cold MLB,
again centrifuging each time and discarding the super-
natant. After the final wash, 40μl of 2× Laemmli reducing
sample buffer containing 50 mM DTT (to improve release
of RhoA from the beads) was added and the mixture was
boiled at 95°C for 5 min, followed by cooling and storage
at −20°C or below. The final supernatant and agarose
pellet were mixed before being subjected to SDS-PAGE
and western blot, as described below.
RhoA-EmGFP/ARHGEF1-EmGFP translocation imaging
and quantification
Coverslips containing serum-starved hASMCs were
mounted on to a Zeiss Axiovert 200 microscope and cells
were visualized using a BD CARV II Confocal Imager
under ×40 magnification, bathed in PSS/5% CO2 at
37°C. When illuminated with UV/blue light (390 nm),
successfully transfected cells were identified by bright
green fluorescence. RhoA-EmGFP/ARHGEF1-EmGFP
translocation was stimulated by acute application of 1 μM
BK. Images were captured by MetaFluor v.7 software
(Molecular Devices, Sunnyvale, CA, USA). This typically
involved brief (65 ms) shutter openings, once every 2 s
during stimulation, but less frequently during rest periods.
Regional and temporal changes in fluorescence, indicating
movement of the EmGFP-tagged protein in response to
drug treatments, were quantified using ImageJ software
C© 2017 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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(rsb.info.nih.gov). Briefly, a line was drawn across each
region of interest centred around spots or patches on the
cell periphery. For each region, a single value of difference
in fluorescence between the ‘spot’ peak intensity and
nearby background was determined. Each region of inter-
est was measured before and during exposure to BK in the
same cell. Two or three regions of interest were analysed
and averaged for each cell and BK-induced fluorescence
expressed as a percentage of control. The only criteria for
exclusion of a cell from the analysis was poor EmGFP
transfection, indicated by overall cellular fluorescence
below a pre-determined threshold level.
hASMC acute treatment, harvesting and western blot
SrcFK, MYPT1, MLC20 and cofilin phosphorylation/
de-phosphorylation was stimulated by acute treatment
with BK (1 μM, 30 s) in serum-free DMEM at 37°C, as
shown previously (Shaifta et al. 2015). Cells were then
immediately washed twice with ice-cold PBS (Invitrogen,
Carlsbad, CA, USA) to terminate reactions and remove
any residual media, followed immediately by application
of cell lysis buffer (New England Biolabs, Ipswich, MA,
USA) containing 1% phosphatase inhibitor cocktails 2
and 3 and 1% protease inhibitor cocktail (all Sigma). Cells
were scraped into a tube, agitated continuously for 30 s,
placed on ice and centrifuged at 10000 r.p.m. for 5 min.
The resultant pellets were discarded and the remaining
supernatant was stored at −80°C for future use.
Protein contentwas determinedusing thebicinchoninic
acid assay, calibrated against BSA protein standards. Prior
to gel loading for SDS-PAGE, lysates were prepared in
NuPAGE LDS Sample Buffer (Invitrogen) and protein
content was adjusted so that each lane of the gel would
typically contain 20 μg of protein. Samples were boiled
at 95°C for 5 min before being loaded onto 4–12%
NuPAGEBis-Tris gels (Invitrogen). Gels were run inMops
running buffer (Invitrogen) and proteinwas transferred to
nitrocellulose membrane (GE Healthcare, Little Chalfont,
UK) in transfer buffer (25 mM Tris, 192 mM glycine, 20%
methanol).
Membranes were blocked with 5% skimmed milk
in Tris-buffered saline (TBS), followed by incubation
with specific anti-phospho-protein primary antibody
(typically 1:1000 dilution) in TBS with 1% skimmed
milk and 0.1% Tween-20 (TBS-T), overnight at 4°C.
This was then followed by washes in TBS-T and the
application of appropriate HRP-conjugated secondary
antibody (typically 1:5000 dilution) for 1 h at room
temperature, followed by further washes in TBS-T.
‘Phospho’ proteinswere visualizedwith Super-SignalWest
Femto chemi-luminescent Substrate (Thermo Scientific,
Waltham, MA, USA). Membranes were then stripped in
Restore western blot stripping buffer (Thermo Scientific),
re-blocked and re-incubated with corresponding ‘total’
antibody and appropriate secondary antibodies, as above.
‘Total’ proteins were visualized with either ECL plus or
ECL prime (GE Healthcare). All images were captured
and quantified using the ChemiDoc XRS+ gel imaging
system (Bio-Rad, Hercules, CA, USA).
Changes in protein expression were determined as a
ratio of the target protein signal over signal for the
‘housekeeping’ protein GAPDH, acting as a loading
control for each sample. An estimate of the amount of
targetprotein thatwasphosphorylated in response toacute
treatments was calculated both as a ratio of ‘phospho’ over
‘total’ signal for each protein sample, to give an indication
of the fraction of each protein that is phosphorylated in
response to BK, and as a ratio of ‘phospho’ over GAPDH,
to reveal the influence of TGF-β and ARHGEF1 siRNA on
total phosphorylation of each protein, in addition to the
acute effect of BK. The effects of treatments on these ratios
were then expressed as a percentage of control (no BK, no
TGF-β, run on the same gel).
Materials and reagents
Antibodies were obtained from: Cell Signaling [Danvers,
MA, USA: anti-phospho-Src (tyr416), anti-Src, anti-
phospho-MLC (ser19), anti-MLC, anti-MYPT1, anti-
p115RhoGEF, anti-RhoA, anti-cofilin, anti-phospho-
cofilin (ser3)], Millipore [anti-phospho-MYPT1
(thr696)], Sigma (anti-rabbit IgG, anti-mouse IgG) and
Santa Cruz Biotechnology (Santa Cruz, CA, USA: anti-
ROCK2). All antibodies were used at 1:1000 dilution
except for anti-phospho-MYPT1, anti-rabbit IgG and
anti-mouse IgG, which were used at 1:5000. PP2 [4-
amino-5-(4-chlorophenyl)-7-(dimethylethyl) pyrazolo[3,
4-d]pyrimidine] was obtained from Calbiochem; BK,
Y16 (inhibitor of RGS-domain containing RhoGEFs)
and Y27632 (Rho-kinase inhibitor) were obtained from
Sigma. Rhotekin reagent and GTP-γ-S were obtained
from Millipore. TGF-β was obtained from R&D Systems
(Minneapolis, MN, USA). Cell culture and western
blot materials were from Cell Signaling, Invitrogen, GE
Healthcare or Thermo Scientific. General reagents were
from Sigma, Calbiochem or VWR (Radnor, PA, USA).
Data analysis and statistics
All values are expressed as mean ± SEM. All
statistical analysis and non-linear regression curve fitting
was performed with SigmaPlot 10. BK concentration
responses were biphasic, so were fitted using a two-site
saturation model, for the characterization of a high
affinity component (PD2-1 and Max-1) and a low
affinity component (PD2-2 and Max-2). In contraction
experiments, ‘n’ refers to the number of bronchioles
obtained from a similar number of rats. In western blot
experiments, ‘n’ refers to the number of cell cultures,
C© 2017 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
52 Y. Shaifta and others J Physiol 596.1
each derived from a different human subject. In trans-
location experiments, ‘n’ refers to the number of cells,
selected at random from at least three separate cell
cultures, each derived from a different human subject.
Statistical comparisons were by paired or un-paired t test
(two groups of data, single factor), one-way, two-way or
three-way ANOVA (multiple comparisons, single factor,
two-factor or three-factor, respectively), with Holm-Sidak
post-tests where appropriate, and as indicated in figure or
table legends. Differences were considered significant at
P < 0.05.
Results
TGF-β enhances BK-induced constriction via RhoGEFs
and Rho-kinase, but not SrcFK
The contractile effects of BK (0.01–100 μM) on iso-
lated rat bronchioles were determined with or without
prior exposure to TGF-β. The BK dose response was
then repeated in each bronchiole in the presence of
the SrcFK inhibitor PP2 (30 μM), the inhibitor of RGS
domain-containing RhoGEFs Y16 (30 μM; Shang et al.
2013) or the Rho-kinase inhibitor Y27632 (10 μM).
At each dose, BK produced a biphasic contraction,
incorporating a large transient which usually decayed
to a near plateau within 5 min. Non-linear regression
analysis of the plateau phase at each concentration showed
that the data were best fitted to a two-site saturation
model with a high and a low affinity component. In
the absence of inhibitor, TGF-β enhanced the contra-
ctile response compared to media alone (Fig. 1A and B).
Specifically, the amplitude of the low affinity component
(Bmax-2) was increased by TGF-β (Fig. 1F), while other
parameters were unaltered (Fig. 1F and G). All three
inhibitors partially suppressed BK-induced contraction,
after both media and TGF-β pre-incubation (Fig. 1C–E),
showing significant reductions in amplitude of both high
and low affinity components (Bmax-1 and Bmax-2).
However, there remained a significant difference in Bmax2
between media and TGF-β pre-treated bronchioles in
the presence of PP2, while in the presence of Y16
or Y27632 these differences were no longer significant.
Other curve-fit parameters were unaffected by the three
inhibitors, regardless of pre-exposure to TGF-β or media
alone (Fig. 1G). TGF-β pre-exposure did not alter the
amplitude of KPSS-induced constriction compared to
media (media only: 2.9 ± 0.4 mN, n = 49 vs. TGF-β:
3.0 ± 0.4 mN, n = 49). Repeating BK dose-responses in
the absence of inhibitor (time controls), in bronchioles
exposed to TGF-β or media alone, showed no changes in
any of the curve-fit parameters (n = 4, data not shown).
To see how the interaction between SrcFK inhibition
and TGF-β pre-incubation on BK-induced contraction
relates to SrcFK expression and activity, we determined
the effects of TGF-β on c-Src protein expression in
hASMCs. We found that acute treatment with BK
(30 s, 1 μM) enhanced SrcFK auto-phosphorylation,
but that this enhancement was not potentiated by
prior exposure to TGF-β and that pre-exposure
to TGF-β reduced c-Src protein content by 30%
(Fig. 2A and B). To account for the effect of altered
c-Src content on SrcFK phosphorylation, changes in
auto-phosphorylation were expressed in two ways:
phospho/total, a proportional measure of the degree
of phosphorylation (Fig. 2C), and phospho/GAPDH,
a measure of actual phosphorylated SrcFK content,
relative to total cellular protein (Fig. 2D). Without prior
incubation with TGF-β, acute exposure to BK produced
a 2-fold increase in SrcFK auto-phosphorylation, while
after TGF-β pre-incubation the enhancing effect of BK
was significantly reduced. Basal SrcFK phosphorylation
was also suppressed by TGF-β, but only when expressed as
phospho/GAPDH, linking it to the reduced c-Src protein
content.
TGF-β enhances ARHGEF1 expression, while BK
triggers ARHGEF1 translocation
Considering that the TGF-β-induced enhancement of
contraction is dependent on RhoGEFs and Rho-kinase,
we next examined the effects of TGF-β on expression,
activity and translocation of RhoA, expression and activity
of Rho-kinase and the influence of theRhoGEFARHGEF1
on those effects, in hASMCs. TGF-β had no effect on
protein expression of either RhoA or Rho-kinase, relative
to GAPDH (Fig. 3A and B) but induced a doubling
in protein content of ARHGEF1, relative to GAPDH
(Fig. 3C). In hASMCs transfected with EmGFP-tagged
ARHGEF1, fluorescence was concentrated in the peri-
nuclear region, but with lower levels in the cell peri-
phery. Addition of BK (1 μM) reversibly enhanced
this fluorescence in distinct peripheral patches or spots
(Fig. 3D), indicating that ARHGEF1 translocates to these
regions in response to stimulation by BK.
TGF-β influences RhoA activity and translocation: role
of ARHGEF1
Although TGF-β does not alter expression of RhoA or
Rho-kinase, it may alter their activity and/or cellular
localization via the enhanced expression of ARHGEF1.
Therefore, we next determined whether TGF-β influences
RhoA/Rho-kinase activity by examining the effects of
pre-exposure to TGF-β on RhoA-GTP content and
MYPT1 and MLC20 phosphorylation in hASMCs. We
also examined the effects of TGF-β on RhoA-EmGFP
translocation. To determine whether any of these changes
were mediated via ARHGEF1, the effects of ARHGEF1
siRNA on these parameters were also investigated.
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Figure 1. Effects of TGF-β and SrcFK/RhoGEF/Rho-kinase inhibition on BK-induced contraction
Measurement of isometric tension in isolated rat bronchioles mounted on the wire myograph. A, representative
traces showing bradykinin (BK) applied cumulatively (0.01–100 μM) at 5 min intervals, after 18 h pre-incubation in
media only or in media with 30 ng ml−1 TGF-β. Arrows indicate when the first dose of BK was applied. B–E, mean
contraction amplitude after TGF-β or media pre-incubation measured at the plateau phase of each BK application,
in the absence (B, media: n = 24, TGF-β: n = 23) or presence of 30 μM PP2 (C, media: n = 17, TGF-β: n = 15),
30 μM Y16 (D, media: n = 9, TGF-β: n = 9) or 10 μM Y27632 (E, media: n = 9, TGF-β: n = 9). F and G, non-linear
regression data, showing effects of TGF-β and inhibitors on Bmax (F) and PD2 values (G). ∗P < 0.05 vs. control,
#P < 0.05 vs. media, two-way ANOVA.
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Figure 2. Effects of BK and TGF-β on SrcFK expression and
auto-phosphorylation in hASMC
A, representative blots showing effect of BK (1 μM, 30 s) with or
without prior exposure to TGF-β (10 ng ml−1, 24 h) on
phospho-SrcFK content, total c-Src content and GAPDH as a loading
control. B, data expressed as c-Src/GAPDH show partial inhibition of
c-Src protein expression after TGF-β pre-incubation (#P < 0.05 vs.
–TGF-β, n = 7). C and D, SrcFK phosphorylation is enhanced by BK
(∗P < 0.05, ∗∗P < 0.01 vs. control, n = 7), but suppressed by TGF-β
(#P < 0.01, ##P < 0.01 vs. –TGF-β, n = 7). All comparisons by
two-way ANOVA.
Transfection of hASMCs with ARHGEF1 siRNA
produced an approximately 75% reduction in ARHGEF1
protein expression compared to transfection with a
scrambled siRNA (Fig. 3C). Figure 4 shows the effects of
BK, TGF-β and ARHGEF1 siRNA on RhoA-GTP content,
a direct measure of total cellular RhoA activity. The
positive control GTPγS consistently caused a several-fold
increase in RhoA-GTP content relative to total RhoA
(986 ± 69%, n = 7). As expected, BK also caused a
several-fold increase in RhoA activity and this increase
was significantly inhibited in hASMCs transfected with
an ARHGEF1 siRNA compared to a scrambled (control)
siRNA (Fig. 4A and C). The effect of BK was also partially
suppressed by TGF-β, but it was still further suppressed
by the siRNA, resulting in no overall effect of TGF-β
on the BK-induced response in hASMCs transfected
with ARHGEF1 siRNA (Fig. 4A and C). Neither TGF-β
nor ARHGEF1 siRNA affected RhoA-GTP content in
the absence of BK, and total RhoA content relative to
GAPDH was not affected by any of the treatments used
(Fig. 4B).
In hASMCs transfectedwithRhoA-EmGFP, application
of BK induced a modest enhancement of fluorescence
in the cell periphery (Fig. 5A). After prior incubation
with TGF-β, this BK-induced translocation was enhanced
and was increasingly characterized by the appearance or
intensification of spots/patches at the cell periphery or
on cellular projections (Fig. 5B). A similar pattern of
BK-induced RhoA-EmGFP translocation was observed
in hASMCs exposed to TGF-β and transfected with
scrambled siRNA (Fig. 5C), while translocation was not
observed inhASMCsexposed toTGF-β andco-transfected
with ARHGEF1 siRNA (Fig. 5D).
TGF-β enhances MYPT-1/MLC20 expression and
phosphorylation in hASMC: role of ARHGEF1
Considering that RhoA activates Rho-kinase, which in
turn enhances MLC20 phosphorylation via inhibition
of MLCP, we next examined the effects of TGF-β pre-
incubation and ARHGEF1 siRNA on protein expression
and BK-induced phosphorylation of MLC20 itself and of
MYPT1, which when phosphorylated on Th696 results in
MLCP inhibition.
Pre-incubation with TGF-β almost doubled the protein
expression of MYPT1 in hASMCs transfected with the
scrambled siRNA (relative to GAPDH). The ARHGEF1
siRNA did not alter this increase (Fig. 6A and B). To
account for changes in totalMYPT1 content, we expressed
changes in MYPT1 phosphorylation in two ways: relative
to total MYPT1 (phospho/total, Fig. 6C) and relative
to total cellular protein (phospho/GAPDH, Fig. 6D).
In hASMCs transfected with scrambled siRNA and not
pre-incubated with TGF-β, acutely applied BK enhanced
MYPT1 phosphorylation. In hASMCs pre-incubated
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with TGF-β, both basal and BK-induced MYPT1
phosphorylation was enhanced. This enhancement was
greatest when expressed as phospho/GAPDH, but was
still evident when expressed as phospho/total. In hASMCs
transfected with ARHGEF1 siRNA, acute application of
BK was unable to enhance MYPT1 phosphorylation,
regardless of whether hASMCs were first incubated
with TGF-β or not. In hASMCs transfected with
ARHGEF1 siRNA, TGF-β still enhanced basal MYPT1
phosphorylation, but to a much lesser extent than in
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Figure 3. Effects of TGF-β and BK on ARHGEF1 expression and translocation
A–C, effects of TGF-β incubation (10 ng ml−1, 24 h) on protein expression of RhoA (A, n = 6), Rho-kinase (B,
ROCK2, n = 5) and ARHGEF1 (C, after transfection with scrambled or ARHGEF1 siRNA, n = 9) in hASMCs, relative
to GAPDH. ∗∗P < 0.01 vs. –TGF-β, ##P < 0.01 vs. scrambled siRNA, two-way ANOVA. D, fluorescence imaging
of live hASMCs transfected with ARHGEF1-EmGFP. Arrows indicate peripheral regions in which ARHGEF1-EmGFP
concentrates when stimulated by addition of BK (1 μM). Data show relative changes in fluorescence in peripheral
regions. ∗∗P < 0.01 vs. control, n = 11, paired t test.
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hASMCs transfectedwith scrambled siRNA.Furthermore,
this residual enhancing effect of TGF-β pre-incubation
was only evident when the data were expressed as
phospho/GAPDH.
In cells transfected with scrambled siRNA, MLC20
protein content was increased 3-fold by TGF-β (relative
to GAPDH). Unlike with MYPT1, this increased protein
expression was partially reversed in cells transfected with
ARHGEF1 siRNA (Fig. 7A and B). As with MYPT1,
to account for TGF-β-induced MLC20 protein content,
changes in MLC20 phosphorylation were expressed in two
ways: relative to total MLC20 (phospho/total, Fig. 7C)
or relative to total cellular protein (phospho/GAPDH,
Fig. 7D).
In hASMCs transfected with scrambled siRNA and
not pre-incubated with TGF-β, acutely applied BK
enhanced MLC20 phosphorylation, as expected. After
incubation with TGF-β, BK still caused an increase in
phosphorylation, but the overall effect of TGF-β on
basal and BK-induced MLC20 phosphorylation depended
on the way the data were expressed. When expressed
as total/phospho, an approximately 30% suppressing
effect of TGF-β on phosphorylation was indicated, but
when expressed as phospho/GAPDH, an approximately
2-fold enhancing effect of TGF-β on phosphorylation was
indicated.
In hASMCs transfected with ARHGEF1 siRNA, acute
application of BK was unable to significantly enhance
MLC20 phosphorylation, regardless of whether hASMCs
were first incubated with TGF-β or not. This inhibitory
action of ARHGEF1 siRNA was evident with either way
the data were expressed, but was most evident when
they were expressed as phospho/total (Fig. 7C). Trans-
fecting hASMCs with ARHGEF1 siRNA weakened the
effects of TGF-β on MLC20 phosphorylation compared
to ASM transfected with scrambled siRNA: it prevented
the apparent TGF-β-induced suppression when data
were expressed as phospho/total and it suppressed the
TGF-β-induced enhancement when data were expressed
as phospho/GAPDH.
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Figure 4. Effects of TGF-β and ARHGEF1
siRNA on RhoA-GTP content in hASMCs
A, representative blots showing effects of
acute BK treatment (1 μM, 30 s) with or
without TGF-β pre-treatment (10 ng ml−1,
24 h) in hASMCs transfected with either
ARHGEF1 siRNA or a scrambled siRNA control
on RhoA-GTP content, total RhoA or GAPDH
as a loading control. B, data expressed as
total/GAPDH show no overall effect of BK,
TGF-β or ARHGEF1 siRNA on total RhoA
expression. C, data expressed as
RhoA-GTP/total show significant
enhancement by BK (∗∗P < 0.01 vs. control)
but partial suppression by TGF-β (##P < 0.01,
vs. –TGF-β) and ARHGEF1 siRNA ($P < 0.05,
$$P < 0.01 vs. scrambled siRNA). n = 7 for all
data. All comparisons by three-way ANOVA.
C© 2017 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
J Physiol 596.1 TGF-β, ARHGEF1 and Rho-kinase in airway smooth muscle 57
−TGF-βA
B
C
D
−TGF-β
+TGF-β
+TGF-β
+TGF-β
ARHGEF1 siRNA
control BK
**
+TGF-β
+TGF-β scrambled siRNA Scrambled siRNA
+TGF-β ARHGEF1 siRNA
control
control
x2 x2
30μm
30μm
20μm
control
control
15μm
BK
200
160
120
80
40
0
200 **
##
160
120
80
40
0
control BK
control BK
control BK
##
**
200
160
120
80
40
0
200
160
120
80
40
0
BK
BK
BK
P
er
ip
he
ra
l R
ho
A
-E
m
G
F
P
 fl
uo
re
sc
en
ce
 (
%
 c
on
tr
ol
)
P
er
ip
he
ra
l R
ho
A
-E
m
G
F
P
 fl
uo
re
sc
en
ce
 (
%
 c
on
tr
ol
)
Figure 5. Effects of TGF-β and ARHGEF1 siRNA on BK-induced RhoA-EmGFP translocation
Fluorescence imaging of live hASMCs transfected with RhoA-EmGFP. A, in the absence of TGF-β pre-incubation,
addition of BK (1 μM) enhances peripheral fluorescence, as indicated by arrows. ∗∗P < 0.001 vs. control, n = 16.
B, after TGF-β pre-incubation (10 ng ml−1, 24 h), response to BK is enhanced and is concentrated into distinct
peripheral spots/patches, as indicated by arrows. ∗∗P < 0.001 vs. control, ##P < 0.001 vs. –TGF-β, n = 15. C,
in hASMCs pre-treated with TGF-β, doubly transfected with RhoA-EmGFP and scrambled siRNA, response to
BK is similar to in B, as indicated by arrows. ∗∗P < 0.001 vs. control, n = 28. D, in hASMCs pre-treated with
TGF-β, co-transfected with RhoA-EmGFP and ARHGEF1 siRNA, BK does not trigger translocation. ##P < 0.001 vs.
scrambled siRNA, n = 29. All comparisons by two-way ANOVA.
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BK and TGF-β influence cofilin phosphorylation: role
of ARHGEF1
In cells transfected with scrambled siRNA, cofilin protein
content was increased approximately 2-fold by TGF-β
(relative to GAPDH). This increased protein expression
was partially reversed in cells transfected with ARHGEF1
siRNA (Fig. 8A and B). As with MYPT1 and MLC20,
basal and BK-induced changes in cofilin phosphorylation
were expressed in two ways: relative to total cofilin
(phospho/total, Fig. 8C) or relative to total cellular
protein (phospho/GAPDH, Fig. 8D). In hASMCs trans-
fected with scrambled siRNA but not treated with TGF-β,
acute application of BK caused an approximately 50%
de-phosphorylation of cofilin, while in TGF-β pre-treated
hASMCs, this BK-induced de-phosphorylation was
prevented. In the absence of TGF-β pre-treatment,
ARHGEF1 siRNA had no effect on the BK-induced cofilin
de-phosphorylation, but in TGF-β-treated hASMCs the
siRNA partially but significantly restored the BK-induced
cofilin de-phosphorylation. When data were expressed
as phospho/GAPDH, there was also a TGF-β-induced
increase in total cofilin phosphorylation and a partial
suppression of this effect by the ARHGEF1 siRNA
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Figure 6. Effects of TGF-β and ARHGEF1
siRNA on expression and BK-induced
phosphorylation of MYPT-1 in hASMCs
A, representative blots showing effects of acute
BK treatment (1 μM, 30 s) with or without TGF-β
pre-treatment (10 ng ml−1, 24 h) in hASMCs
transfected with either ARHGEF1 siRNA, or a
scrambled siRNA control, on phospho-MYPT-1
(Thr-696), total MYPT1 or GAPDH as a loading
control. B, data expressed as total/GAPDH show
enhancement of MYPT1 protein expression by
TGF-β pre-treatment, but no effect of ARHGEF1
siRNA or BK, ##P < 0.01 vs. –TGF-β. Data
expressed as phospho/total (C) or
phospho/GAPDH (D) show significant
enhancement by both BK (∗P < 0.05, ∗∗P < 0.01
vs. control) and TGF-β (#P < 0.05, ##P < 0.01 vs.
–TGF-β) and suppression by ARHGEF1 siRNA
($P < 0.05, $$P < 0.01 vs. scrambled siRNA).
n = 9 for all data. All comparisons by three-way
ANOVA.
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(Fig. 8D). These effects presumably relate to the influence
of TGF-β on total cofilin protein content.
Given the importance of ARHGEF1 in the above
described effects of TGF-β on RhoA/Rho-kinase and
cofilin, we also compared ARHGEF1 protein expression
in healthy vs. asthmatic hASMCs and in lung
of OVA-sensitized vs. sham-treated mice. ARHGEF1
expression was higher in hASMCs of asthmatic donors
compared to healthy controls and was higher in lung of
OVA-sensitized mice compared to lung of sham-treated
controls (Fig. 9).
Discussion
The results of this study show that TGF-β enhances
BK-induced contraction in isolated rat bronchioles
and enhances BK-induced RhoA-EmGFP translocation
and MYPT-1 and MLC20 phosphorylation in hASMCs,
without potentiating BK-induced enhancement of total
cellular RhoA activity. Conversely, TGF-β suppresses
BK-induced SrcFK auto-phosphorylation and cofilin
de-phosphorylation. The effects of BK and TGF-β
on RhoA-EmGFP translocation and activity and
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Figure 7. Effects of TGF-β and ARHGEF1
siRNA on expression and BK-induced
phosphorylation of MLC20 in hASMCs
A, representative blots showing effects of acute
BK treatment (1 μM, 30 s) with or without TGF-β
pre-treatment (10 ng ml−1, 24 h) in hASMCs
transfected with either ARHGEF1 siRNA, or a
scrambled siRNA control, on phospho-MLC20
(Ser19), total MLC20 or GAPDH as a loading
control. B, data expressed as total/GAPDH show
enhancement of MLC20 protein expression by
TGF-β pre-treatment (##P < 0.01 vs. –TGF-β),
and partial suppression of this response by
ARHGEF1 siRNA ($$P < 0.01 vs. scrambled
siRNA). Data expressed as phospho/total (C) or
phospho/GAPDH (D) show significant
enhancement by both BK (∗P < 0.05, ∗∗P < 0.01
vs. control), effects of TGF-β pre-treatment
(#P < 0.05, ##P < 0.01 vs. –TGF-β) and
suppression by ARHGEF1 siRNA ($P < 0.05,
$$P < 0.01 vs. scrambled siRNA). n = 9 for all
data. All comparisons by three-way ANOVA.
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MYPT-1/MLC20/cofilin phosphorylation are mediated in
part by the guanine nucleotide exchange factorARHGEF1.
RhoA/Rho-kinase and SrcFK are all implicated in
ASM responses to bronchoconstrictors (Chiba et al.
2001; Shaifta et al. 2015). Thus, both pathways have
been suggested as potential novel therapeutic targets
for asthma (Schaafsma et al. 2008; Katsumoto et al.
2013). We hypothesized that these signalling pathways
may be altered by the inflammatory mediator TGF-β,
an important modulator of ASM phenotype, also
implicated in asthma (McMillan et al. 2005). We found
that, at concentrations similar to those detected in
the airways of asthmatic patients (Redington et al.
1997; Torrego et al. 2007), pre-incubation with TGF-β
enhanced BK-induced contractile responses in isolated
rat bronchioles. The BK concentration response was
biphasic, as described previously (Shaifta et al. 2015),
and TGF-β selectively enhanced the amplitude of the
low-affinity component. Although TGF-β reportedly
induces hypertrophy of ASMCs (Halwani et al. 2011), an
increased smooth muscle mass is unlikely to account for
our observed effects of TGF-β on BK-induced contraction
because KPSS-induced contraction was unaffected by
TGF-β.
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Figure 8. Effects of BK, TGF-β and
ARHGEF1 siRNA on cofilin expression and
phosphorylation in hASMCs
A, representative blots showing effects of
acute BK treatment (1 μM, 30 s) with or
without TGF-β pre-treatment (10 ng ml−1,
24 h) in hASMCs transfected with either
ARHGEF1 siRNA, or a scrambled siRNA control,
on phospho-cofilin (Ser3), total cofilin or
GAPDH as a loading control. B, data expressed
as total/GAPDH show enhancement of cofilin
protein expression by TGF-β pre-treatment
(##P < 0.01 vs. –TGF-β), and partial
suppression of this response by ARHGEF1
siRNA ($$P < 0.01 vs. scrambled siRNA). Data
expressed as phospho/total (C) or
phospho/GAPDH (D) show significant
de-phosphorylation induced by BK (∗∗P < 0.01
vs. control), prevention of
de-phosphorylation/enhancement of basal
phosphorylation by TGF-β pre-treatment
(#P < 0.05, ##P < 0.01 vs. –TGF-β) and partial
suppression of the effects of TGF-β by
ARHGEF1 siRNA ($$P < 0.01 vs. scrambled
siRNA). n = 7 for all data. All comparisons by
three-way ANOVA.
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SrcFK inhibition with PP2 partially suppressed the
bronchiole contractile response to BK and BK treatment
enhanced SrcFK auto-phosphorylation in hASMCs, as
shownpreviously (Shaifta et al. 2015). Conversely, PP2 did
not prevent the proportionate enhancing action of TGF-β
on contraction compared to media alone, and TGF-β
exerted a distinct inhibitory action on Src expression and
activity. Thus, even though TGF-β reportedly mediates
some of its SMAD-independent effects via activation
of SrcFK (Samarakoon et al. 2008), our results suggest
that although SrcFK may contribute to normal contra-
ctile responses in ASMCs, they do not contribute
to the TGF-β-mediated enhancement of BK-induced
contraction. This is perhaps related to previous evidence
that TGF-β enhances SrcFK protein degradation as part of
its anti-proliferative action (Atfi et al. 1994; Fukuda et al.
1998).
Wealsopreviously showed thatBK-inducedcontraction
in rat bronchioles is heavily dependent on Rho-kinase
activity and that BK enhances phosphorylation of the
Rho-kinase target MYPT1 in hASMCs, in line with
that of MLC20 (Shaifta et al. 2015), suggesting a strong
contribution of Rho-kinase-dependent MLCP inhibition
to the contractile response (Somlyo & Somlyo, 2003). In
the present study, the TGF-β-mediated enhancement of
BK-induced contraction was abolished by the Rho-kinase
inhibitor Y27632 and by Y16, an inhibitor of the RGS
domain-containing sub-family of Rho-specific guanine
nucleotide exchange factors (ARHGEF1, ARHGEF11 and
ARHGEF12) (Shang et al. 2013). Therefore, the effects
of TGF-β on contraction are likely to be mediated
via enhanced expression or activity of components
of the RhoGEF/RhoA/Rho-kinase signalling pathway.
Investigating this further, we found that TGF-β had no
effect on relative protein content of either RhoA or
Rho-kinase in hASMCs, but enhanced relative protein
content of ARHGEF1, and downstream targets MYPT1,
MLC20 as well as the actin severing protein cofilin. If
protein content of RhoA and Rho-kinase were unaltered
by TGF-β, then perhaps their activity is being enhanced
via the TGF-β-mediated upregulation of ARHGEF1. We
therefore examined RhoA activity directly (Rhotekin
assay) and its subcellular translocation, which is often
taken as a corollary of activity (but see below), together
with activity of Rho-kinase (MYPT1 phosphorylation)
and MLC20 phosphorylation.
Measured using the Rhotekin assay, BK clearly causes
activation of RhoA, as indicated by a several-fold increase
in total cellular RhoA-GTP content relative to total
RhoA. Significant suppression of this response by the
ARHGEF1 siRNA confirms the importance of ARHGEF1
to RhoA activation by BK in hASMCs. Similarly, we
found that BK triggered subcellular translocation of
both ARHGEF1-EmGFP and RhoA-EmGFP to the peri-
phery of live hASMCs and that the RhoA-EmGFP trans-
location was abolished by co-transfecting hASMCs with
ARHGEF1 siRNA. TGF-β also enhanced the BK-induced
RhoA-EmGFP translocation, and this enhancement was
abolished in hASMCs co-transfected with an ARHGEF1
siRNA, suggesting a relationship between the effects
of TGF-β on ARHGEF1 expression and its effects on
BK-induced RhoA-EmGFP translocation. Surprisingly,
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Figure 9. Effects of asthma and OVA-sensitization on lung ARHGEF-1 protein expression
Protein expression of ARHGEF-1 relative to GAPDH. Expression is enhanced by OVA-sensitization in mouse lung (A,
∗P < 0.05 vs. sham-treated, n = 3 in each group) and is greater in ASM of asthmatic subjects vs. healthy controls
(B, ∗P < 0.05, n = 3 subjects in each group). All comparisons by unpaired t test.
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however, in hASMCs transfected with scrambled siRNA,
TGF-β did not enhance the BK-induced increase in
RhoA-GTP content but partially suppressed it, while
in cells transfected with ARHGEF1 siRNA, TGF-β
had no effect. Thus, following TGF-β treatment, there
is a dissociation between RhoA-EmGFP translocation
and RhoA activity. This is discussed further below in
conjunction with the effects of BK, TGF-β and ARHGEF1
siRNA on MYPT1 phosphorylation.
RhoA activates Rho-kinase, and a good indicator of
Rho-kinase activity is the degree of phosphorylation of
MYPT1, which when phosphorylated at Thr696 triggers
inhibition of MLCP, resulting in a net enhancement
of MLC20 phosphorylation at any given [Ca2+]i (Feng
et al. 1999). We therefore examined the effects of
TGF-β pre-treatment and the ARHGEF1 siRNA on
BK-induced MYPT1 and MLC20 phosphorylation in
hASMCs. Normally, protein phosphorylation data are
expressed as a ratio of ‘phospho’ over ‘total’ for each
protein (e.g. P-MYPT1/MYPT1), to control for random
variations in total content of each protein. However, when
the treatment clearly also alters the expression of that
protein, as is the case with our TGF-β pre-treatments,
phospho-protein content will be influenced by both
the relative activity of the kinase responsible for the
phosphorylation and the availability of the protein being
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Figure 10. Role of ARHGEF1, SrcFK, RhoA, Rho-kinase and cofilin in BK-induced contraction in ASM and
the influence of TGF-β on their relative contributions
Without TGF-β treatment. It is established that G-protein coupled receptor (GPCR)-induced ASM contraction
is dependent on sequential activation of RhoA and Rho-kinase, resulting in MYPT1 phosphorylation, MLCP
inhibition and enhanced MLC20 phosphorylation. We show that BK also induces SrcFK activation and trans-
location of ARHGEF1. RhoA translocation and activation, MYPT1 and MLC20 phosphorylation are all partially
ARHGEF1-dependent. Also, contraction is partially SrcFK-, RhoGEF- and Rho-kinase-dependent. SrcFK possibly
act upstream of ARHGEF1 (but not tested in this study). BK inhibits cofilin phosphorylation, but how this
influences contraction remains to be determined. After TGF-β treatment. Expression and BK-induced activity
of c-Src are suppressed, while expression of ARHGEF1, MYPT1, MLC20 and cofilin are enhanced. BK-induced RhoA
activity is partially suppressed, while RhoA translocation, MYPT-1 phosphorylation, MLC20 phosphorylation and
contraction are all enhanced. Enhancement of RhoA translocation andMYPT1/MLC20 phosphorylation are partially
ARHGEF1-dependent, while enhanced contraction is Rho-kinase and RhoGEF-dependent. Enhanced Rho-kinase
activity may result from enhanced site-specific RhoA translocation, to counter the reduced total RhoA activity, or
from activation of another Rho-protein (both untested in this study). Cofilin phosphorylation is enhanced, but is
largely independent of ARHGEF1 and whether this contributes to enhanced contraction remains to be determined.
Key: size of text/box reflects degree of protein expression. Size of ‘P’ reflects degree of phosphorylation. Thickness
of lines/arrows reflects strength of effect. The row of block arrows represents translocation. (?) or (±?) denotes
‘not tested in this study’.
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phosphorylated. For this reason, phosphorylation data
were expressed both as phospho/total, giving a measure
of relative Rho-kinase activity, and as phospho/GAPDH,
giving a measure of actual phospho-protein content
relative to total cellular protein content. As expected,
BK induced an increase in MYPT1 phosphorylation,
while TGF-β enhanced phosphorylation in both the
absence and the presence of BK. This is broadly in
line with its enhancing effect on RhoA-EmGFP trans-
location but not with its partial suppressing effect on
total RhoA-GTP content. The relative increases inMYPT1
phosphorylation were evident regardless of the way the
data were expressed, suggesting that the effect of TGF-β
was jointly due to increased Rho-kinase activity and
increased availability of MYPT1 for phosphorylation.
The ARHGEF1 siRNA did not alter the TGF-β-mediated
enhancement ofMYPT1 protein content, but rendered the
phosphorylation responses to BK statistically insignificant
and greatly suppressed the enhancing effect of TGF-β
on this phosphorylation, especially when the data were
expressed as phospho/total. These results provide clear
evidence that ARHGEF1 is required for Rho-kinase
activity in hASMCs, in both the presence and the absence
of TGF-β.
It is unclear why TGF-β enhances RhoA-EmGFP
translocation and Rho-kinase activity but partially
suppresses BK-induced enhancement of total cellular
RhoA-GTP content. Translocation of native RhoA to
the cell membrane/periphery as visualized by immuno-
histochemistry is often taken as a corollary of RhoGEF or
GTPase activation (Chiba et al. 2004; Meyer et al. 2008)
because it is assumed that translocation represents the
movement of the RhoGEF to be activated by G12/13 or
movement of RhoA to be activated by RhoGEFs. However,
here we have examined the translocation of transfected
RhoA-EmGFP. The advantage of this method is that we
were able to see the localization of the protein both in
the absence and in the presence of BK in the same cell,
but a potential disadvantage is that the attachment of GFP
at the C-terminal of RhoA may have interfered with pre-
nylation of the protein and therefore its correct insertion
into the cell membrane. Thus, the observed translocation
may not be as direct a corollary of RhoA activity as it
would otherwise be, although both are still dependent on
ARHGEF1, albeit to varying degrees. Whatever the reason
for the discrepancy between RhoA-EmGFP translocation
and RhoA activity, TGF-β is clearly enhancing Rho-kinase
activity in ASM and this enhancement is dependent
on ARHGEF1. The TGF-β-induced enhancement of
ARHGEF1 expression could possibly result in a greater
fraction of active RhoA being directed to parts of the
cell where RhoA is able to activate Rho-kinase, resulting
in enhanced MYPT1 phosphorylation, despite an over-
all reduction in total cellular RhoA-GTP. Alternatively,
TGF-β might induce a shift away from activation of
Rho-kinase by RhoA towards activation of Rho-kinase by
another small G-protein, such as RhoB (Vasilaki et al.
2010), which has also been reported to be activated
by ARHGEF1 in other cell types (Jaiswal et al. 2011).
Considerable further work will be required to fully
characterize theways inwhichRhoGEF/RhoA/Rho-kinase
signalling complexes are influenced by TGF-β in ASM and
whether other Rho proteins also play a part.
Quantifying MLC20 phosphorylation reflects the
balance between MLCK and MLCP activity as well as
the total amount of MLC20 available for phosphorylation.
TGF-β induced a 3-fold increase in relativeMLC20 protein
content. This has the potential to support a 3-fold increase
in cross-bridge cycling and contraction, but for such an
increase to occur there needs to be a similar fold shift in the
balance betweenMLCK andMLCP activity. In the absence
of TGF-β or ARHGEF1 siRNA, BK enhanced MLC20
phosphorylation, as expected, but how this response
was influenced by TGF-β depended on the way the
data were expressed. When expressed as phospho/total,
TGF-β appeared to partially suppress both basal and
BK-induced phosphorylation, but when expressed as
phospho/GAPDH, it caused an approximate 2-fold
enhancement. A possible explanation for this discrepancy
is that MLC20 protein expression was increased by
a greater amount (3-fold) than was total MLC20
phosphorylation (phospho/GAPDH, 2-fold), resulting
in an apparent reduction in relative phosphorylation
(phospho/total) because not all of the extra MLC20 was
being phosphorylated. Nevertheless, a 2-fold increase in
total MLC20 phosphorylation could support a similar
increase in actin-myosin cross-bridge cycling, bearing in
mind that TGF-β also enhances expression of myosin
heavy chain and α-actin in ASMCs (Goldsmith et al.
2006; Oenema et al. 2012), and MLCK in other cell types
(Rossi et al. 2011). By also examining the inhibitory effects
of ARHGEF1 siRNA on MLC20 phosphorylation we are
able to confirm that BK-induced phosphorylation and the
enhancing effect of TGF-βwere primarily due to increases
in Rho-kinase activity downstream of ARHGEF1, since
the siRNA abolished the effects of TGF-β on the
phospho/total signal, which is proportional to relative
Rho-kinase activity. Interestingly, the TGF-β-induced
enhancement of MLC20 protein expression was also
partially dependent on ARHGEF1, supporting previous
evidence for RhoA/Rho-kinase contributing to TGF-β-
induced contractile protein expression (Zhao et al. 2007;
Tsapara et al. 2010; Ji et al. 2014). In retinal epithelium,
TGF-β enhances expression of another RhoGEF, GEF-H1
(Tsapara et al. 2010), but to our knowledge this study
provides the first evidence that ARHGEF1 is important
in TGF-β-induced enhancement of both ASM contractile
protein expression and cross-bridge cycling.
Cofilin is a key mediator of cellular actin dynamics. By
severing actin fibres and leaving barbed ends, it reduces
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the number of available contractile fibres, while on the
other hand it increases the number of nucleation sites for
the creation of new branched fibres (Albinsson et al. 2004;
Andrianantoandro & Pollard, 2006; Leduc et al. 2016).
In the absence of TGF-β pre-treatment, we found that
BK triggered an approximately 50% de-phosphorylation
of cofilin, and that this effect was unaltered by the
ARHGEF1 siRNA, suggesting no role for ARHGEF1, and
therefore potentially no role for RhoA/Rho-kinase, in the
regulation of cofilin activity (Zhang et al. 2015).
These results are consistent with a previous report in
tracheal smooth muscle, where acetylcholine activates
the phosphatase PP2B, which de-phosphorylates and
activates cofilin (Zhao et al. 2008). As they suggest,
this makes sense if cofilin provides a pool of G actin
from which new contractile fibres and their attachments
can be made (Zhao et al. 2008), rather than causing
a net reduction in actin polymerization, as reportedly
occurs in other smooth muscles (Zeidan et al. 2007;
Dai et al. 2008). Interestingly, after pre-incubation with
TGF-β, BK no longer induced de-phosphorylation
of cofilin, while at the same time cofilin expression
was enhanced. Considering that TGF-β also reportedly
enhances actin polymerization in lung slices (Oenema
et al. 2013), an alternative interpretation of the role of
cofilin is that bronchoconstrictors could be activating
PP2B and cofilin as a ‘braking action’ against theirMLCK/
Rho-kinase-dependent pro-contractile actions (Vardouli
et al. 2005; Sandbo et al. 2011). Thus TGF-β could poten-
tially be removing the ‘brake’ by causing a shift in favour of
cofilin phosphorylation and inhibition of its actin severing
activity. However, regardless of whether these effects of
TGF-β on cofilin are pro-contractile or otherwise, they
are only modestly influenced by ARHGEF1. The effects
of the siRNA are to partially reverse the TGF-β-induced
enhancement of cofilin expression and to only partially
restore the BK-induced cofilin de-phosphorylation. Thus,
ARHGEF1 is likely to be of minimal importance to
TGF-β-mediated effects on actin polymerization.
In summary, our results show that TGF-β enhances
Rho-kinase activity and Rho-kinase-dependent
contraction in ASM. Furthermore, ARHGEF1, a Rho-
specific guanine nucleotide exchange factor, is an
important mediator of both the normal BK-induced
responses and their enhancement by TGF-β (summarized
in Fig. 10). In light of these findings and previous
evidence showing the contribution of TGF-β to airway
remodelling and hyper-contractility (Redington et al.
1997; Matsunaga et al. 2006; Torrego et al. 2007), we also
show that ARHGEF1 is itself upregulated in hASMCs of
asthmatic donors compared to healthy controls and is
enhanced in lung of OVA-sensitized mice compared to
sham-treated controls. Although a direct link between
ARHGEF1, enhanced smooth muscle Rho-kinase activity
and abnormal airway function in asthmatic airways
remains to be determined, our study supports previous
work implicating ARHGEF1 in asthmatic T lymphocyte
cytokine production (Brown et al. 2007), making it a
prime candidate for pharmacological intervention in
airway responsiveness and asthma.
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